Glenmark gets US nod to market Mupirocin skin cream

Pharmaceutical company Glenmark's US subsidiary Glenmark Generics has received final approval from US Food and Drugs Administration for its abbreviated new drug application for Mupirocin Calcium Cream USP, 2 percent.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset
moneycontrol.com

Home » News » Business

Jan 28, 2013, 02.16 PM | Source: Moneycontrol.com

Glenmark gets US nod to market Mupirocin skin cream

Pharmaceutical company Glenmark's US subsidiary Glenmark Generics has received final approval from US Food and Drugs Administration for its abbreviated new drug application for Mupirocin Calcium Cream USP, 2 percent.

Like this story, share it with millions of investors on M3

Glenmark gets US nod to market Mupirocin skin cream

Pharmaceutical company Glenmark's US subsidiary Glenmark Generics has received final approval from US Food and Drugs Administration for its abbreviated new drug application for Mupirocin Calcium Cream USP, 2 percent.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Pharmaceutical company Glenmark 's US subsidiary Glenmark Generics has received final approval from US Food and Drugs Administration for its abbreviated new drug application for Mupirocin Calcium Cream USP, 2 percent.

Mupirocin Calcium Cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length) caused by bacteria such as S aureus and S pyogenes, Glenmark said on Monday.

The cream had US sales of USD 56.5 million for the year-ended Sept 2012, it added, citing IMS Health data.

Glenmark now has 83 products authorized for distribution in the US and a further 46 ANDAs are pending approval with the FDA.

Glenmark shares hit a high of Rs 534.80 in morning trade on Monday and at 9:45 hrs, it was up 0.5 percent at Rs 517.35.

Also Read: Hexaware says not lost any clients; company on growth track  

Glenmark stock price

On May 24, 2016, Glenmark Pharma closed at Rs 858.70, down Rs 1.45, or 0.17 percent. The 52-week high of the share was Rs 1261.95 and the 52-week low was Rs 671.50.


The company's trailing 12-month (TTM) EPS was at Rs 52.04 per share as per the quarter ended March 2016. The stock's price-to-earnings (P/E) ratio was 16.5. The latest book value of the company is Rs 227.58 per share. At current value, the price-to-book value of the company is 3.77.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Glenmark gets US nod to market Mupirocin skin cream

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login